Iovance’s Australian Amtagvi Nod Adds Test For Valuation Upside

Simply Wall St.06-05

Iovance Biotherapeutics received conditional approval from Australia's TGA for Amtagvi, its cell therapy for advanced melanoma. This is Amtagvi's third marketing authorization and extends access to a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641816064?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-06-05 05:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641816064","market":"nz","top_or_hot":-1,"title":"Iovance’s Australian Amtagvi Nod Adds Test For Valuation Upside","media":"Simply Wall St.","content":"<div>\n<p>Iovance Biotherapeutics received conditional approval from Australia's TGA for Amtagvi, its cell therapy for advanced melanoma. This is Amtagvi's third marketing authorization and extends access to a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/iovances-australian-amtagvi-nod-adds-test-for-valuation-upsi\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iovance’s Australian Amtagvi Nod Adds Test For Valuation Upside</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIovance’s Australian Amtagvi Nod Adds Test For Valuation Upside\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-05 05:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/iovances-australian-amtagvi-nod-adds-test-for-valuation-upsi><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Iovance Biotherapeutics received conditional approval from Australia's TGA for Amtagvi, its cell therapy for advanced melanoma. This is Amtagvi's third marketing authorization and extends access to a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/iovances-australian-amtagvi-nod-adds-test-for-valuation-upsi\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZYAU.AU","symbol_name":"Etfs S&p/asx 300 High Yield Plus Etf","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/iovances-australian-amtagvi-nod-adds-test-for-valuation-upsi","article_id":"2641816064","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/iovances-australian-amtagvi-nod-adds-test-for-valuation-upsi","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641816064","pubTimestamp":1780608898,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Iovance Biotherapeutics received conditional approval from Australia's TGA for Amtagvi, its cell therapy for advanced melanoma.\nThis is Amtagvi's third marketing authorization and extends access to a market with one of the highest melanoma rates globally.\n\nThe news adds a fresh angle for Iovance Biotherapeutics (NasdaqGM:IOVA), which has recently drawn attention around US developments but less so around its international reach. The stock trades at $3.79 and has gained 50.4% year to date and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZYAU.AU":"Etfs S&p/asx 300 High Yield Plus Etf","BK4139":"生物科技","IISV.AU":"INTELL INV SELVAL SHR FD MF","VAP.AU":"VANGUARD AU PROP SEC IDX ETF","VAS.AU":"VANGUARD AUST SHARES IDX ETF","GIVE.AU":"PERPETUAL ESG AU SHR EQMF","EIGA.AU":"EINVEST INCOME GENERATOR FD","GEAR.AU":"BETASHARES GEARED AUS EQTY F","OZF.AU":"SPDR S&P/ASX 200 FINANCIALS","IOZ.AU":"iShares Core S&P/ASX 200","STW.AU":"SPDR® S&P/ASX 200 ETF","OZR.AU":"SPDR S&P/ASX 200 RESOURCES F","BBOZ.AU":"BETASHARES AUSTRALIAN STRONG BEAR (HEDGE FUND)","DACE.AU":"DIMENSIONAL AUST CORE EQ","E200.AU":"SPDR S&P/ASX 200 ESG FUND","XAO.AU":"标普/澳交所 普通股指数","SLF.AU":"SPDR S&P/ASX 200 LISTED PROP","BEAR.AU":"BETASHARES AUS EQ BEAR HF","XJO.AU":"标普/澳交所 200指数","IMLC.AU":"INV MUTUAL CONC AUS SHAR ETF","IIGF.AU":"Intelligent Investor Australian Equity Growth Fund (Managed Fund)","XKO.AU":"标普/澳交所 300指数","QFN.AU":"BetaShares Australian Fincls Sect ETF","QRE.AU":"BetaShares Australian Res Sect ETF","IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"Iovance的澳大利亚Amtagvi点头增加了估值上行的考验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZYAU.AU":0.6,"IIGF.AU":0.6,"IMLC.AU":0.6,"XAO.AU":1.5,"IISV.AU":0.6,"SLF.AU":0.6,"XKO.AU":1.5,"OZF.AU":0.6,"OZR.AU":0.6,"QRE.AU":0.6,"QFN.AU":0.6,"DACE.AU":0.6,"STW.AU":0.6,"BBOZ.AU":0.6,"GEAR.AU":0.6,"BEAR.AU":0.6,"XJO.AU":1.5,"GIVE.AU":0.6,"E200.AU":0.6,"VAP.AU":0.6,"VAS.AU":0.6,"EIGA.AU":0.6,"IOVA":0.9,"IOZ.AU":0.6},"content_text":"Iovance Biotherapeutics received conditional approval from Australia's TGA for Amtagvi, its cell therapy for advanced melanoma. This is Amtagvi's third marketing authorization and extends access to a market with one of the highest melanoma rates globally.  The news adds a fresh angle for Iovance Biotherapeutics (NasdaqGM:IOVA), which has recently drawn attention around US developments but less so around its international reach. The stock trades at $3.79 and has gained 50.4% year to date and 107.1% over the past year, while being down 54.0% over three years and 81.6% over five years. That mix of strong recent and weaker longer term returns means many investors are still weighing how durable the latest progress might be. Australia's conditional green light broadens the commercial footprint for Amtagvi and gives Iovance exposure to a key melanoma market outside the US. Investors will likely focus on how quickly the company can translate this approval into treated patients, real world data and a more geographically diverse revenue base, while watching for any further regulatory updates in other regions. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page. NasdaqGM:IOVA Earnings & Revenue Growth as at Jun 2026 3 things going right for Iovance Biotherapeutics that this headline doesn't cover. AdvertisementQuick Assessment  ✅ Price vs Analyst Target: At $3.79 versus a consensus target of $8.80, the stock trades about 57% below analyst expectations. ✅ Simply Wall St Valuation: Simply Wall St estimates the shares are trading roughly 86% below fair value, flagging them as undervalued. ❌ Recent Momentum: The stock has slipped 1.6% over the past 30 days, so the near term trend has been slightly negative.  There is only one way to know the right time to buy, sell or hold Iovance Biotherapeutics. Head to Simply Wall St's\ncompany report for the latest analysis of Iovance Biotherapeutics's Fair Value. Key Considerations  📊 The Australian conditional approval for Amtagvi adds another commercial market, which ties the investment case more tightly to execution in melanoma cell therapy. 📊 Watch how treated patient numbers, real world outcomes and any updates to revenue expectations evolve as the therapy rolls out in a high incidence melanoma country. ⚠️ Recent shareholder dilution and a volatile share price history mean you should pay close attention to future funding moves and capital structure.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete Iovance Biotherapeutics analysis. Alternatively, you can check out the\ncommunity page for Iovance Biotherapeutics to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641816064","isCrawlerRequest":true}